BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34610423)

  • 1. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
    Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
    Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
    Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
    Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Yang Y; Wang K; Chen H; Feng Z
    Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Evaluation of
    OuYang Y; Gao J; Zhao L; Lu J; Zhong H; Tang H; Jin S; Yue L; Li Y; Guo W; Xu Q; Lai Y
    J Med Chem; 2021 Jun; 64(11):7646-7666. PubMed ID: 34037385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors.
    Zhang M; Liu J; Wang Y; Wang P; Morris-Natschke S; Lee KH
    Bioorg Med Chem; 2022 Jan; 54():116579. PubMed ID: 34954618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold.
    Qin M; Cao Q; Wu X; Liu C; Zheng S; Xie H; Tian Y; Xie J; Zhao Y; Hou Y; Zhang X; Xu B; Zhang H; Wang X
    Eur J Med Chem; 2020 Jan; 186():111856. PubMed ID: 31734021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint.
    Zhu P; Zhang J; Yang Y; Wang L; Zhou J; Zhang H
    Mol Divers; 2022 Feb; 26(1):245-264. PubMed ID: 33786726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage.
    Song Z; Liu B; Peng X; Gu W; Sun Y; Xing L; Xu Y; Geng M; Ai J; Zhang A
    J Med Chem; 2021 Nov; 64(22):16687-16702. PubMed ID: 34761679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors?
    Riccio A; Coletti A; Dolciami D; Mammoli A; Cerra B; Moretti S; Gioiello A; Ferlin S; Puxeddu E; Macchiarulo A
    ChemMedChem; 2021 Feb; 16(3):568-577. PubMed ID: 33085193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
    Dai X; Wang K; Chen H; Huang X; Feng Z
    Bioorg Chem; 2021 Sep; 114():105034. PubMed ID: 34116264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
    Wu Y; Zhang Y; Guo Y; Pan Z; Zhong S; Jin X; Zhuang W; Chen S; Gao J; Huang W; Dong X; Che J
    Eur J Med Chem; 2021 Nov; 223():113637. PubMed ID: 34147746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.
    Zhang Y; Yin F; Luo Z; Li S; Li X; Wan S; Chen Y; Kong L; Wang X
    Eur J Med Chem; 2024 May; 271():116433. PubMed ID: 38678826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Wang Y; Kun Huang ; Gao Y; Yuan D; Ling L; Liu J; Wu S; Chen R; Li H; Xiong Y; Liu H; Ma J
    Eur J Med Chem; 2022 Feb; 229():113998. PubMed ID: 34839997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
    J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
    Cheng B; Ren Y; Cao H; Chen J
    Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
    Kim EH; Kawamoto M; Dharmatti R; Kobatake E; Ito Y; Miyatake H
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugation of biphenyl groups with poly(ethylene glycol) to enhance inhibitory effects on the PD-1/PD-L1 immune checkpoint interaction.
    Kim EH; Ning B; Kawamoto M; Miyatake H; Kobatake E; Ito Y; Akimoto J
    J Mater Chem B; 2020 Nov; 8(44):10162-10171. PubMed ID: 33095222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
    Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
    Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[
    Liu L; Yao Z; Wang S; Xie T; Wu G; Zhang H; Zhang P; Wu Y; Yuan H; Sun H
    J Med Chem; 2021 Jun; 64(12):8391-8409. PubMed ID: 34115499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
    Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
    Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.